Author： Jakobsen Jan Nyrop Hasselbalch Benedikte Stockhausen Marie-Thééréése Lassen Ulrik Poulsen Hans Skovgaard
Publisher： Informa Healthcare
ISSN： 1465-6566
Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.5, 2011-04, pp. : 825-833
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Bevacizumab ± irinotecan beneficial for glioblastoma
Inpharma, Vol. 1, Iss. 1640, 2008-01 ,pp. :
Access to resources
Recommend
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
By Chang Susan Wen Patrick Cloughesy Timothy Greenberg Harry Schiff David Conrad Charles Fink Karen Robins H. Angelis Lisa Raizer Jeffrey Hess Kenneth Aldape Ken Lamborn Kathleen Kuhn John Dancey Janet Prados Michael
Investigational New Drugs, Vol. 23, Iss. 4, 2005-08 ,pp. :
Bevacizumab: In Previously Treated Glioblastoma
Drugs, Vol. 70, Iss. 2, 2010-01 ,pp. :